器官來(lái)源：大腦
是否是腫瘤細(xì)胞：0
物種來(lái)源：褐鼠
年限：fetus, 20 days gestation
運(yùn)輸方式：凍存運(yùn)輸
生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
ATCC Number：CRL-2397?
相關(guān)疾?。浩渌膊?br />
細(xì)胞形態(tài)：其他
數(shù)量：大量
規(guī)格：48T Designations: F98
Depositors: ?RF Barth
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Rattus norvegicus
Morphology:glial
Source: Organ: brain
Disease: undifferentiated malignant glioma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Age: fetus, 20 days gestation
Comments:This tumor was produced by Drs. A. Koestner and W. Wechsler at The Ohio State University in 1971.
A pregnant CD Fischer rat on day 20 of gestation was inoculated with a single dose of N-ethyl-N-nitrosourea (ENU) (50 mg/kg b.w.). Tumors were harvested and cloned. [38592 ]
This cell line may be used for both in vitro and in vivo studies of a rat brain tumor. It grows well in cell culture and provides a simple, reproducible glioma model when inoculated into the brains of syngeneic rats.
The biological characteristics of this tumor closely resemble those of human glioblastoma.
The transplantable tumor displays an infiltrative pattern of growth within the brain. [38611 ]
It is weakly immunogenic in syngeneic rats and an intracerebral inoculum of as few as 100 cells are lethal. [38613 ]
The F98 and RG2 (ATCC CRL-2433 ) gliomas can be used as rat brain tumor models in experimental neuro-oncology. [39801 ]
F98 was submitted to the American Type Culture Collection in June, 1998 at passage 2 from a culture established from a subcutaneous tumor grown in a male Fischer rat.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol:
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.05% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:10 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 38592: Ko L, et al. Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol. 51: 23-31, 1980. PubMed: 7435138
38606: Tzeng JJ, et al. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. 50: 4338-4343, 1990. PubMed: 2364388
38610: Barth RF, et al. Boron Neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood brain barrier disruption. Cancer Res. 57: 1129-1136, 1997. PubMed: 9067283
38611: Clendenon NR, et al. Boron neutron capture therapy of a rat glioma. Neurosurgery 26: 47-55, 1990. PubMed: 2294479
38612: Matalka KZ, et al. Neutron capture therapy of a rat glioma using boronophenylalanine as a capture agent. Radiat. Res. 137: 44-51, 1994. PubMed: 8265787
38613: Tzeng JJ, et al. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res. 51: 2373-2378, 1991. PubMed: 2015600
38614: Gyngell ML, et al. Localized proton NMR spectroscopy of experimental gliomas in rat brain in vivo. NMR Biomed. 5: 335-340, 1992. PubMed: 1336973
38615: Bockhorst K, et al. Localization of experimental brain tumors in MRI by gadolinium porphyrin. Acta Neurochir. Suppl. (Wien) 60: 347-349, 1994. PubMed: 7976586
38616: Els T, et al. NMR contrast enhancement of brain tumors: Comparison of the blood brain barrier tracer GdDTPA and the tumor-selective contrast agent in MnTPPS. MAGMA 1: 126-133, 1993.
38617: Hossmann KA, et al. Regional metabolism of experimental brain tumors. Acta Neuropathol. 69: 139-147, 1986. PubMed: 3962590
38621: Eis M, et al. High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magn. Reson. Med. 34: 835-844, 1995. PubMed: 8598810
38622: Eis M, et al. Quantitative diffusion MR imaging of cerebral tumor and edema. Acta Neurochir. Suppl. (Wien) 60: 344-346, 1994. PubMed: 7976585
38623: Judy KD, et al. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J. Neurosurg. 82: 481-486, 1995. PubMed: 7861228
38624: Ernestus RI, et al. Identification of intracranial liqor metastases of experimental stereotactically implanted brain tumors by the tumor-selective MRI contrast agent MnTPPS. Clin. Exp. Metastasis 10: 345-350, 1992. PubMed: 1505124
38625: Yang W, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption. Int. J. Radiat. Oncol. Biol. Phys. 37: 663-672, 1997. PubMed: 9112465
38626: Yang W, et al. Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine. J. Neuro-Oncol. 33: 59-70, 1997. PubMed: 9151224
38627: Boucher Y, et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br. J. Cancer 75: 829-836, 1997. PubMed: 9062403
38629: Barba D, et al. Tumor immunity, immunizations and herpes simplex virus-thymidine kinase mediated tumor regression. Abstr. 1st Scientific Meeting Soc. Neuro-Onco. : 1996..
39799: Vinores SA, Koestner A. The effect of nerve growth factor on undifferentiated glioma cells. Cancer Lett. 10: 309-318, 1980. PubMed: 7427924
39800: Kobayashi N, et al. An improved rat brain-tumor model. J. Neurosurg. 53: 808-815, 1980. PubMed: 7003068
39801: Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neuro-Oncol. 36: 91-102, 1998. PubMed: 9525831
